Holen Sie sich die Stockscreener-App
1.60
2.44%
-0.04
Handel nachbörslich:
2.58
0.98
+61.25%
Schlusskurs vom Vortag:
$1.64
Offen:
$1.64
24-Stunden-Volumen:
13,274
Relative Volume:
0.39
Marktkapitalisierung:
$13.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-1.14M
KGV:
-3.8095
EPS:
-0.42
Netto-Cashflow:
$-2.11M
1W Leistung:
-9.09%
1M Leistung:
-6.43%
6M Leistung:
-23.81%
1J Leistung:
-21.57%
1-Tages-Spanne:
$1.59
$1.85
1-Wochen-Bereich:
$1.56
$1.94
52-Wochen-Spanne:
$1.39
$2.58
Pharmacyte Biotech Inc Stock (PMCB) Company Profile
Firmenname
Pharmacyte Biotech Inc
Sektor
Branche
Telefon
(917) 595.2850
Adresse
23046 AVENIDA DE LA CARLOTA, SUITE 600, LAGUNA HILLS
Vergleichen Sie PMCB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| PMCB | 2.24 | 0 | 0 | 0 | 0 | 0.00 |
| GOODO | 22.16 | 372.90M | 0 | 0 | 0 | 0.00 |
| PSNYW | 0.141 | 297.56M | 2.07B | -1.42B | -1.37B | -0.1344 |
| MOBBW | 0.16 | 278.60M | 0 | 0 | 0 | 0.00 |
| SHMD | 2.61 | 114.98M | 0 | 0 | 0 | 0.00 |
| JUNE | 4.95 | 63.87M | 0 | 0 | 0 | 0.00 |
Pharmacyte Biotech Inc Aktie (PMCB) Neueste Nachrichten
Malignant Ascites Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - openPR
Top 10 startups in In Vitro Diagnostics in Atlanta, United States in Oct, 2024 - Tracxn
Pharos Energy Advances Buyback, Reduces Share Capital - TipRanks
PPBT stock touches 52-week low at $5.89 amid market challenges By Investing.com - Investing.com South Africa
Proteomics International Laboratories (ASX:PIQ) presenting at the Pitt Street Research Life Sciences Conference 2024 - Stocks Down Under
POET Technologies (CVE:PTK) Trading Up 14.6% - MarketBeat
Small Cap Stocks: Plexus, Parkmead, Proton Motor - The Armchair Trader
PDS Biotechnology: Continuing The Holding Pattern (NASDAQ:PDSB) - Seeking Alpha
Tri Locum Partners LP Trims Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Westwood Holdings Group Inc. Has $572,000 Stock Holdings in Patterson Companies, Inc. (NASDAQ:PDCO) - Defense World
Pre-IPO Zhejiang Taimei Medical Technology (PHIP Updates)Some Points Worth the Attention - Smartkarma
Texas Permanent School Fund Corp Sells 6,500 Shares of Bio-Techne Co. (NASDAQ:TECH) - Defense World
Biotech stocks are an unappreciated way to profit from lower rates, Goldman says - Head Topics
Pancreatic Cancer Market Status Analysis, Scope, Trend, Capacity and Forecast 2024-2033 - Cauverynews
PharmaCyte Biotech, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2024 - Marketscreener.com
Encapsulated Live Cell Market to Record Rapid Revenue Growth from 2024 to 2031 - Elektrotransports.lv
Pancreatic Cancer Treatment Market Size Worth USD 10.53 - GlobeNewswire
Pancreatic Cancer Treatment Market Size Worth USD 10.53 Billion by 2032 Driven by Rising Prevalence of Obesity, Smoking, and Alcohol Consumption | Research by SNS Insider - GlobeNewswire Inc.
Financial Analysis: PharmaCyte Biotech (OTCMKTS:PMCBD) vs. INmune Bio (NASDAQ:INMB) - Defense World
PMCB stock touches 52-week low at $1.75 amid market challenges - Investing.com Australia
500: Something went wrong - Investing.com India
TNF Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
TNF Pharmaceuticals, Inc. announced that it expects to receive $14 million in funding from PharmaCyte Biotech, Inc. - Marketscreener.com
PharmaCyte Biotech (OTCMKTS:PMCBD) Shares Down 1.9% - Defense World
Avant Technologies Announces Leadership Shake-Up and New CEO - TipRanks
Live Cell Encapsulation Market 2024 Growth Analysis by Market Es - WICZ
Live Cell Encapsulation Market 2024 Growth Analysis by Market Estimation, Manufacturers, Product Types Gross Margin and Forecast to 2030 - WICZ
Pancreatic Beta-Cell Protection Market Analysis and Revenue Prediction | ViaCyte, PharmaCyte Biotech, Boehringer ... - Economica
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Down 2.4% - Defense World
PharmaCyte Biotech (NASDAQ:PMCB) Trading Down 2.4% - Defense World
Pancreatic Cancer Market is expected to surpass USD 7,541.09 Million by 2033, growing at a 13.5% annual rate | FMI Study - Market Research Blog
Pancreatic Cancer Market is expected to surpass USD 7,541.09 Million by 2033, growing at a 13.5% ann - PharmiWeb.com
Malignant Ascites Market Report 2034: Epidemiology, Pipeline The - News Channel Nebraska
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Up 2% - Defense World
PharmaCyte Biotech (NASDAQ:PMCB) Stock Price Up 2% - Defense World
PharmaCyte Biotech's Diabetes Treatment: How Would It Work? - Yahoo Movies UK
Critical Analysis: PharmaCyte Biotech (OTCMKTS:PMCBD) vs. LENZ Therapeutics (NASDAQ:LENZ) - Defense World
MyMD Pharmaceuticals secures $7M investment from PharmaCyte Biotech - TipRanks
PharmaCyte Biotech announces $7 million strategic investment in MYMD - MSN
MyMD Pharmaceuticals Secures Strategic Investments - citybiz
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on ... - Winchester Herald Chronicle
Ascites Treatment Market Emerging Trends | Sequana Medical, BioVie, PharmaCyte Biotech - Motions Online
PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business - Simply Wall St
Pharmacyte Biotech Inc (OTCMKTS:PMCB) Is At A Turning Point - Insider Financial
Femasys secures nearly $7M in funding from PharmaCyte - Mass Device
Ascites Market Exploring Market Trends and Growth: A 2030 Forecast Report | IMR Market Report - Newstrail
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology - Business Wire
PharmaCyte Biotech Announces Final Results of Tender Offer - Business Wire
PharmaCyte Biotech Announces Cash Tender Offer for up to 7750000 Shares at $3.25 Per Share - Business Wire
Trend Innovations Holding, Inc. Appoints Kenneth L. Waggoner as Chief Executive Officer - GlobeNewswire
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan - Business Wire
Finanzdaten der Pharmacyte Biotech Inc-Aktie (PMCB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):